9 Sep

Biologics patent thicketing problem getting worse, says Fresenius’ IP chief

Fresenius Kabi’s Rachel Moodie argues that written description rules and a weak IPR system allow for significant IP thicketing in the US. The patent estates of newer blockbusters like Keytruda, she says, suggest the problem will only get worse for biosimilars.

Adam Houldsworth

Author | Life sciences reporter

[email protected]

Adam Houldsworth